晚期非小细胞肺癌患者三种治疗方案经济学评价  

Economic Evaluation of Three Treatment Regimens for Advanced Non-small Cell Lung Cancer

作　　者：陈昌明[1] 刘杰[1] 张英[1] 林洪生[1] CHEN Chang-ruing;LIU Jie;ZHANG Ying;LIN Hong-sheng(Department of Oncology, Guang＇anmen Hospital, China Academy of Chinese Medical Sciences, Beifing 100083, China)

机构地区：[1]中国中医科学院广安门医院肿瘤科,北京100053

出　　处：《中国中医基础医学杂志》2018年第4期507-509,529,共4页JOURNAL OF BASIC CHINESE MEDICINE

基　　金：国家十一五科技支撑计划(2006BAI04A05)-非小细胞肺癌中医综合治疗方案的研究

摘　　要：目的:运用药物经济学评价方法,评价晚期非小细胞肺癌的3种治疗方案,探讨经济而有效的治疗方案。方法:采用多中心、前瞻性随机对照研究方法,以瘤体客观缓解率、疾病控制率、无进展生存时间(PFS)及生存期(OS)作为疗效指标,对中医组、西医组和中西医组3种方案进行成本-效果分析。结果:在成本效果比C/EPFS方面,中医组最低(320.01),西医组次之(373.11),中西医组最高(428.73)。在C/EOS方面,中医组与西医组比较差异无统计学意义,而中西医组为260.29,差于其他2组,提示在延长OS方面,中医组和西医组的效费比均优于中西医组。在生存获益方面,中西医组的m OS为461.2 d,优于中医组(331.2 d)和西医组(401.2 d)。结论:中医组的效费比最优,对于老年晚期、体力状态差的患者,单纯中药治疗是一种经济而有效的方案,而对于体力状态好、能够耐受化疗、希望最大限度延长生存的患者,中西医结合是其优选治疗方案。Objective： Using drug economics evaluation method for the comparation of 3 treatment regimens of advanced non-small cell lung cancer（ NSCLC） to explore the economic and effective treatment of advanced NSCLC.Methods： A multicenter,prospective randomized controlled study was conducted. Objective response rate,disease control rate,progression-free survival time（ PFS） and survival time（ OS） were used as the indicators of efficacy. The cost-effect analysis was carried out on the 3 groups of CM group,western medicine group and integrative group. Results： In the costeffective ratio of C/EPFS,CM group was lowest（ 320. 01）,western medicine group followed（ 373. 11）,integrative group highest（ 428. 73）,suggesting that the cost-effective of CM group was best in extended PFS. In the C/EOS： there was no significant difference between CM group and western medicine group,While the integrative group was 260. 29,worse than other 2 groups. Suggesting that the cost-effective of integrative group was worse than CM group and Western medicine group in extended OS. However,the survival of the integrative medicine group was 461. 2 days,which was significantly better than CM group（ 331. 2 days） and the western medicine group（ 401. 2 days）. Conclusion： The cost-effective of CM in the treatment of advanced NSCLC is the most best. CM treatment is an economical and effective methor for elderly,poor advanced NSCLC patients. However,for patients of good financial condition,Chemotherapy tolerance and hope to maximize longevity,integrated Chinese and Western medicine is the preferred treatment.

关 键 词：非小细胞肺癌 中医药 中西医结合 经济学评价 

分 类 号：R734.2[医药卫生—肿瘤]